Outcomes of secondary cancers among myeloma survivors.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 8043-8043 ◽  
Author(s):  
Jorge J. Castillo ◽  
Adam J. Olszewski
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Logistic Models ◽  
Control Analysis ◽  
Cancer Specific Survival ◽  
Biological Difference ◽  
Lung Cancers ◽  
Seer Data ◽  
Index Cancer ◽  
Case Control Analysis

8043 Background: With increasing survival, myeloma patients (pts) experience second cancers. We analyzed receipt of surgery and cancer-specific survival (CSS) among myeloma survivors with common solid tumors, in comparison with pts without myeloma. Methods: We extracted Surveillance, Epidemiology, and End Results (SEER) data on pts diagnosed with common cancers in 2004-2013. Among them, we identified myeloma survivors, and we matched each to 50 randomly sampled controls with the same cancer by age, sex, race, and year of diagnosis. We then compared CSS, cumulative incidence function (CIF) for death from the index cancer (but not from myeloma), and receipt of surgery (for non-metastastic, stage-matched tumors only) using a Cox (for hazard ratio, HR), Fine-Gray (for subhazard ratio, SHR), and conditional logistic models, respectively. Results: Myeloma survivors were significantly older ( P<.001), and more often black (except in bladder cancer) than pts with respective cancers from the general population. In the case-control analysis, breast ( P=.002) and lung cancers ( P=.003) were more often diagnosed at an early stage among myeloma survivors. Receipt of surgery did not significantly differ, except for lower use of prostatectomy in myeloma survivors (odds ratio, 0.59, 95%CI, 0.44-0.81). CSS significantly differed only in lung cancer, and was better among myeloma survivors even when stratified by stage. CIF of cancer death was significantly lower for myeloma cases with lung and colorectal cancer. Conclusions: Despite additional competing mortality from recurrent myeloma, myeloma survivors have similar CSS and CIF of death after common cancers compared with other pts. This highlights the need to treat them similarly to other pts, without assuming a poor prognosis. Better outcomes in lung cancer are not fully explained by earlier detection, suggesting a biological difference. [Table: see text]

Genetic variants in GTF2H1 and risk of lung cancer: A case–control analysis in a Chinese population

Lung Cancer ◽  
2009 ◽  
Vol 63 (2) ◽  
pp. 180-186 ◽  
Author(s):  
Wenting Wu ◽  
Hongliang Liu ◽  
Rong Lei ◽  
Dan Chen ◽  
Shuyu Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Genetic Variants ◽  
Chinese Population ◽  
Case Control ◽  
Control Analysis ◽  
Case Control Analysis

Does multiplicity of synchronous multiple lung primaries (SMLPs) affect prognosis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20530-e20530
Author(s):  
RuoBing Xue ◽  
Satish Maharaj ◽  
Rohit Kumar ◽  
Goetz H. Kloecker
Keyword(s):  
Lung Cancer ◽  
Adjuvant Therapy ◽  
Early Stage ◽  
Primary Lung Cancer ◽  
Case Series ◽  
Current Recommendation ◽  
Lung Cancers ◽  
T Stage ◽  
Wide Range ◽  
Common Risk Factors

e20530 Background: SMLPs are detected more commonly due to advancements in screening technology. Their workup and classification; however, are still lacking a clear standard. T stage of the largest lesion has been used as the major prognostic marker. This; however, does not take the number of SMLPs and their genomic drivers into consideration. This study aims to identify and review common risk factors associated with SMLPs and determine whether the number of primaries influence the prognosis. Methods: A systematic review of the literature published between 2000 and 2021 was conducted through PubMed and Medline by using the combination of keywords, including: “synchronous multiple primary lung cancer”, “simultaneous multifocal lung cancer”, “synchronous solitary lung metastasis”, “risk factor” and “prognosis”. A total of fifty studies were identified, among them only sixteen retrospective research articles and two review articles were relevant to the study at hand. Results: Sixteen retrospective studies including a total of 1685 eligible patients were reviewed. Thirteen of these studies reported the main histology type to be adenocarcinoma with a ratio ranging from 35% to 96.8%. Eight studies have reported the numbers of synchronous primary lung cancers, including one study found 11 SMLPs. Among these, one study by van Rens found number of SMLPs impact prognosis adversely compared to a single lung cancer. However, three other studies demonstrated multiple SMPLs do not adversely affect survival (Finley et al, 2010; Kocaturk et al, 2011; Li et al, 2020). Four of the sixteen studies analysed the effect of multiple lobes involvement and distance between tumors, with varying conclusions; two studies reported no difference in prognosis while one study revealed worse survival with multiple lobe involvement and one study found favorable outcome. Most studies confirm the usual prognostic factors for SMLPs, including: gender, smoking, type of surgery, comorbidities and adjuvant therapy. The median 5 year OS reported for SMLPs is 66%, with a wide range from 19% to 95.8%.The 3 year OS is 75% in most studies. Conclusions: The data on how the number of SMLPs affects the prognosis is uncertain. The current recommendation to base the decision for adjuvant therapy on the highest T stage is not supported by prospective evidence or consistent among published case series. Considering the recent approval of targeted therapies in early stage lung cancers, a better prognostic scoring system for SMLPs is required.

Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: A case-control analysis

Lung Cancer ◽  
2008 ◽  
Vol 60 (3) ◽  
pp. 340-346 ◽  
Author(s):  
Guangfu Jin ◽  
Haifeng Wang ◽  
Zhibin Hu ◽  
Hongliang Liu ◽  
Weiwei Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Chinese Population ◽  
Case Control ◽  
Control Analysis ◽  
Functional Polymorphisms ◽  
Case Control Analysis

scholarly journals Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Baiqiang Dong ◽  
Jin Wang ◽  
Xuan Zhu ◽  
Yuanyuan Chen ◽  
Yujin Xu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Surgical Treatment ◽  
Propensity Score ◽  
Elderly Patients ◽  
Stereotactic Body Radiotherapy ◽  
Early Stage ◽  
Clinical Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cancer Specific Survival

Abstract Background The optimal treatment for elderly patients with early-stage non-small cell lung cancer (NSCLC) remains inconclusive. Previous studies have shown that stereotactic body radiotherapy (SBRT) provides encouraging local control though higher incidence of toxicity in elderly than younger populations. The objective of this study was to compare the outcomes of SBRT and surgical treatment in elderly patients with clinical stage I-II NSCLC. Methods This retrospective analysis included 205 patients aged ≥70 years with clinical stage I NSCLC who underwent SBRT or surgery at Zhejiang Cancer Hospital (Hangzhou, China) from January 2012 to December 2017. A propensity score matching analysis was performed between the two groups. In addition, we compared outcomes and related toxicity in both study arms. Results Each group included 35 patients who met the inclusion criteria. Median follow-up was 50.1 (0.8–74.4) months for surgery and 35.5 (11.5–71.4) months for SBRT. The rate of cancer-specific survival was similar between the two treatment arms (p = 0.958). In patients who underwent surgery, the corresponding 3- and 5-year cancer-specific survival rates were 85.3 and 81.7%, respectively. In those who received radiotherapy, these rates were 91.3 and 74.9%, respectively. Moreover, the 3- and 5-year locoregional control in patients who underwent surgery were 90.0 and 80.0%, respectively. In those who received radiotherapy, these rates were 91.1 and 84.1%, respectively. Notably, the observed differences in progression-free survival were not statistically significant (p = 0.934). In the surgery group, grade 1–2 complications were observed in eleven patients (31%). One patient died due to perioperative infection within 30 days following surgery. There was no grade 3–5 toxicity observed in the SBRT group. Conclusions The outcomes of surgery and SBRT in elderly patients with early-stage NSCLC were similar.

scholarly journals Surgery in high-volume hospitals not commission on cancer accreditation leads to increased cancer-specific survival for early-stage lung cancer

2015 ◽  
Vol 210 (4) ◽  
pp. 643-647 ◽  
Author(s):  
Elizabeth A. David ◽  
David T. Cooke ◽  
Yingjia Chen ◽  
Andrew Perry ◽  
Robert J. Canter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
High Volume ◽  
Cancer Specific Survival ◽  
Early Stage Lung Cancer ◽  
Stage Lung Cancer

scholarly journals Non-small cell lung cancer: the new T1 categories

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 174 ◽  
Author(s):  
Paul E. Van Schil
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
False Positive Rate ◽  
Tnm Staging ◽  
World Health ◽  
Pathological Examination ◽  
Early Stage Lung Cancer ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Lung Cancers

Recently, major changes have occurred in the staging, diagnosis, and treatment of early stage lung cancer. By screening high-risk populations, we are now able to detect lung cancers at an early stage, but the false-positive rate is high. A new pathological classification was published in 2011 and fully incorporated in the 2015 World Health Organisation (WHO) Classification of Tumours of the Lung, Pleura, Thymus, and Heart. The new eighth edition of the tumour–node–metastasis (TNM) staging system has been fully published and will be in use from January 2017. T1 lesions are subdivided into T1a, T1b, and T1c lesions corresponding to lung cancers up to 10 mm, between 11 and 20 mm, and between 21 and 30 mm, respectively. To determine the size, only the solid part on computed tomographic scanning of the chest and the invasive part on pathological examination will be considered. Prognosis is significantly better for the smallest lesions. For some specific subgroups, sublobar resection may be oncologically valid and yield good long-term outcome, but the results of recently performed randomised trials are awaited.

Sign in / Sign up

Export Citation Format

Share Document